Bulimia treated with imipramine: a placebo-controlled, double-blind study.
Bulimia, the syndrome of compulsive binge eating, is a common and often severe disorder frequently resistant to known therapies. Recent evidence suggesting a link between bulimia and affective disorder prompted the authors to perform a double-blind study of imipramine versus placebo with 22 chronically bulimic women. Imipramine was associated with a significantly reduced frequency of binge eating and with improvement on several other measures of eating behavior. On 1- to 8-month follow-up, 18 of the 20 treated subjects (90%) had responded to imipramine or a subsequent antidepressant. This finding augments the growing evidence that bulimia may be related to affective disorder.
D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D001068:Feeding and Eating Disorders / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006963:Hyperphagia / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D007099:Imipramine / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D019964:Mood Disorders / Q000150:complications / Q000188:drug therapy; D010919:Placebos
D000928:Antidepressive Agents; D010919:Placebos; D007099:Imipramine